GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (MEX:BGNE) » Definitions » Shiller PE Ratio

BeiGene (MEX:BGNE) Shiller PE Ratio : (As of Sep. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BeiGene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BeiGene Shiller PE Ratio Historical Data

The historical data trend for BeiGene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Shiller PE Ratio Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeiGene Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BeiGene's Shiller PE Ratio

For the Biotechnology subindustry, BeiGene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeiGene's Shiller PE Ratio falls into.



BeiGene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BeiGene's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, BeiGene's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-21.435/132.5538*132.5538
=-21.435

Current CPI (Jun. 2024) = 132.5538.

BeiGene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -2.439 100.428 -3.219
201412 -1.030 99.070 -1.378
201503 -2.897 99.621 -3.855
201506 -1.647 100.684 -2.168
201509 -4.403 100.392 -5.814
201512 -14.867 99.792 -19.748
201603 -15.665 100.470 -20.667
201606 -14.425 101.688 -18.803
201609 -20.109 101.861 -26.168
201612 -19.535 101.863 -25.421
201703 -24.478 102.862 -31.544
201706 -28.199 103.349 -36.168
201709 47.185 104.136 60.062
201712 -42.830 104.011 -54.583
201803 -37.789 105.290 -47.574
201806 -56.198 106.317 -70.067
201809 -46.201 106.507 -57.500
201812 -89.339 105.998 -111.721
201903 -55.478 107.251 -68.567
201906 -27.469 108.070 -33.692
201909 -100.092 108.329 -122.474
201912 -120.138 108.420 -146.880
202003 -110.285 108.902 -134.238
202006 -99.022 108.767 -120.677
202009 -106.284 109.815 -128.292
202012 -103.438 109.897 -124.763
202103 13.287 111.754 15.760
202106 -104.099 114.631 -120.375
202109 -97.109 115.734 -111.222
202112 -125.341 117.630 -141.244
202203 -85.418 121.301 -93.342
202206 -109.844 125.017 -116.466
202209 -107.213 125.227 -113.486
202212 -83.638 125.222 -88.535
202303 -60.924 127.348 -63.415
202306 -62.404 128.729 -64.258
202309 33.967 129.860 34.672
202312 -59.580 129.419 -61.023
202403 -40.993 131.776 -41.235
202406 -21.435 132.554 -21.435

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeiGene  (MEX:BGNE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BeiGene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BeiGene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.